标签归档：modified

MODIFIED BUFFERED PEPTONE WATER 货号： CM0973

发表于由
MODIFIED BUFFERED PEPTONE WATER
MODIFIED BUFFERED PEPTONE WATER 货号： CM0973MODIFIED BUFFERED PEPTONE WATER 货号： CM0973MODIFIED BUFFERED PEPTONE WATER 货号： CM0973

  • 产品货号：
    CM0973
  • 中文名称：
    MODIFIED BUFFERED PEPTONE WATER
  • 英文名称：
    MODIFIED BUFFERED PEPTONE WATER
  • 品牌：
    OXOID

  • 货号

    产品规格

    售价

    备注

  • CM0973-B

    500g

    ¥646.00

    制成培养基

  • CM0973-M

    2kg

    ¥2518.00

    制成培养基

  • CM0973-R

    2.5kg

    ¥3149.00

    制成培养基

  • CM0973-T

    5kg

    ¥6233.00

    制成培养基

  • CM0973-Z

    25kg

    ¥23503.00

    制成培养基

产品描述

MCC-Modified Daunorubicinol

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

MCC-Modified Daunorubicinol 

Vc-seco-DUBA 是抗体偶联药物的一部分。由 Modified Daunorubicinol (DNA 拓扑异构酶 II 抑制剂)和 ADC linker 连接而成。

MCC-Modified Daunorubicinol

MCC-Modified Daunorubicinol Chemical Structure

CAS No. : 721945-30-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Daunorubicinol is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (DNA Topoisomerase II inhibitor), linked via the ADC linker[1].

IC50 & Target

Daunorubicins/Doxorubicins

 

分子量

776.79

Formula

C39H44N4O13
CAS 号

721945-30-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Samantha Congreve, et al. Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Modified MMAF-C5-COOH

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Modified MMAF-C5-COOH 

Modified MMAF-C5-COOH 是一种 drug-linker conjugate for ADC。

Modified MMAF-C5-COOH

Modified MMAF-C5-COOH Chemical Structure

CAS No. : 1404071-65-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Modified MMAF-C5-COOH is a drug-linker conjugate for ADC[1].

体外研究
(In Vitro)

MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC50s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

954.25

Formula

C51H83N7O10
CAS 号

1404071-65-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added]]. Cancer Res. 2009;69(6):2358-2364.

    [2]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114-124.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Modified MMAF

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Modified MMAF 

Modified MMAF 是一种 ADC 细胞毒素，可用于合成 Antibody-drug Conjugate (ADC)。Modified MMAF 可用于癌的靶向治疗。

Modified MMAF

Modified MMAF Chemical Structure

CAS No. : 1352202-47-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). Modified MMAF can be used for the targeted treatment of cancer[1].

体外研究
(In Vitro)

MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC50s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

840.10

Formula

C45H73N7O8
CAS 号

1352202-47-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added]]. Cancer Res. 2009;69(6):2358-2364.

    [2]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114-124.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Modified MMAF-C5-COOH

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Modified MMAF-C5-COOH 

Modified MMAF-C5-COOH 是一种 drug-linker conjugate for ADC。

Modified MMAF-C5-COOH

Modified MMAF-C5-COOH Chemical Structure

CAS No. : 1404071-65-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Modified MMAF-C5-COOH is a drug-linker conjugate for ADC[1].

体外研究
(In Vitro)

MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC50s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

954.25

Formula

C51H83N7O10
CAS 号

1404071-65-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added]]. Cancer Res. 2009;69(6):2358-2364.

    [2]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114-124.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Modified MMAF

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Modified MMAF 

Modified MMAF 是一种 ADC 细胞毒素，可用于合成 Antibody-drug Conjugate (ADC)。Modified MMAF 可用于癌的靶向治疗。

Modified MMAF

Modified MMAF Chemical Structure

CAS No. : 1352202-47-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). Modified MMAF can be used for the targeted treatment of cancer[1].

体外研究
(In Vitro)

MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC50s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

840.10

Formula

C45H73N7O8
CAS 号

1352202-47-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added]]. Cancer Res. 2009;69(6):2358-2364.

    [2]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114-124.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Modified MMAF-C5-COOH

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Modified MMAF-C5-COOH 

Modified MMAF-C5-COOH 是一种 drug-linker conjugate for ADC。

Modified MMAF-C5-COOH

Modified MMAF-C5-COOH Chemical Structure

CAS No. : 1404071-65-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Modified MMAF-C5-COOH is a drug-linker conjugate for ADC[1].

体外研究
(In Vitro)

MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC50s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

954.25

Formula

C51H83N7O10
CAS 号

1404071-65-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added]]. Cancer Res. 2009;69(6):2358-2364.

    [2]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114-124.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Modified MMAF

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Modified MMAF 

Modified MMAF 是一种 ADC 细胞毒素，可用于合成 Antibody-drug Conjugate (ADC)。Modified MMAF 可用于癌的靶向治疗。

Modified MMAF

Modified MMAF Chemical Structure

CAS No. : 1352202-47-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). Modified MMAF can be used for the targeted treatment of cancer[1].

体外研究
(In Vitro)

MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC50s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

840.10

Formula

C45H73N7O8
CAS 号

1352202-47-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added]]. Cancer Res. 2009;69(6):2358-2364.

    [2]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114-124.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Laminarin, Thiol modified Cat. No. LR-TH-1 2 mg修饰性聚乙二醇

发表于由

上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

Laminarin, Thiol modified

Cat. No. LR-TH-1
Specification
Unit Size 2 mg
Price $385.00

Qty Add to Cart

Synonym: Thiolated laminarin, sulfhydryl modified laminarin, laminarin cystein conjugate.

Description:

Thiol modified laminarin is one of Nanocs polysaccharide derivatives that have thiol/sulfhydryl groups covalently attached to the laminarin backbone. Laminarin, also known as laminaran, is a water soluble polysaccharide of glucose found in brown algae and utilized as a food reserve. Laminarin contains 1,3-linked-beta-d-glucose residues with different degrees of 6-Obranching and beta-(1,6) intrachain links.

Nanocs provides a number of modified laminarin conjugates that can be used for enzymatic activity study and other biomedical research use.

Product Specifications:

  • Form: Lyophilized powder
  • Color: White to off-white
  • Thiolation degree: 0.3-0.5 mmol thiols/g laminarin
  • Source: Laminaria digitata
  • Solubility: Soluble in water

Storage Conditions:

  • Store at -20 0C. 

多肽定制TET 830 modified/T-helper epitope from tetanus toxoid 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 TET 830 modified/T-helper epitope from tetanus toxoid
编码
别名 TET 830 modified/T-helper epitope from tetanus toxoid
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） AQYIKANSKFIGITEL
序列（三字母缩写） H-Ala-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Leu-OH (trifluoroacetate salt)
基本描述 This peptide inhibits binding of one of formyl peptide receptor-like 1 (FPRL1) agonists WKYMVm to its specific receptor. FPRL1 is an important classical chemoattractant receptor that is expressed in phagocytic cells in the peripheral blood and brain. Activation of FPRL1 is closely related to inflammatory responses in the host defense mechanism and neurodegenerative disorders.
溶解度
分子量 1797.2
化学式 C83H134N20O24
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents TET 830 modified/T-helper epitope from tetanus toxoid 编码
Figures TET 830 modified/T-helper epitope from tetanus toxoid 编码
Reference Valmori, D. et al. J. Immunol. 149, 717 (1992) Slingluff, C. Jr. et al. Clin. Cancer Res. 7, 3012 (2001) Slingluff, C. Jr. et al. J. Clin. Oncol. 21, 4016 (2003) Demotz, S. et al. J. Immunol. 142, 394 (1989).
C端
N端
化学桥